Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. High Dividend 20 Index (AUHDIV20)
3/20/2026, 12:00:00 AM
U.S. FDA approved Opdivo (nivolumab) in combination with AVD for the first-line treatment of adult and pediatric patients with previously untreated, Stage III or IV classical Hodgkin Lymphoma.
Korean Translation
미국 FDA, 이전에 치료받지 않은 3기 또는 4기 전형적 호지킨 림프종 성인 및 소아 환자의 1차 치료를 위해 옵디보(니볼루맙)와 AVD 병용 요법을 승인함.
Related Recent Events
Manulife Financial Corp (MFC) · Earnings Release
Manulife scheduled release of Q1 2026 financial results for 2026-05-13 after market close, a routine catalyst with likely modest price impact scheduled.
5/13/2026, 12:00:00 AM
Exelon Corp (EXC) · Earnings Release
Medium importance is estimated as earnings results often drive price moves over 5%; the Q1 2026 earnings release is expected. Analysts' EPS estimate is approximately $0.89 forecasted.
5/7/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
EOG Resources First Quarter 2026 financial results release and conference call on May 6, 2026, as announced on March 24, 2026, scheduled. Low impact estimated as routine quarterly results typically result in <5% price movement.
5/6/2026, 12:00:00 AM
Dominion Energy Inc (D) · Other
Annual shareholder meeting where investors will vote on several proposals, including one calling for an independent board chair. Low importance is estimated as shareholder meetings typically result in minimal immediate price impact, scheduled.
5/5/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Prudential Financial Inc (PRU) · Earnings Release
Prudential Financial is expected to release its Q1 2026 earnings results on or around April 29, 2026, based on past reporting schedules expected.
4/29/2026, 12:00:00 AM